nach oben

Clinical and Translational Oncology

Erschienen in:

12.03.2020 | Research Article

Clinicopathological and prognostic value of hypoxia-inducible factor-1α in breast cancer: a meta-analysis including 5177 patients

verfasst von: Z. Zhao, H. Mu, Y. Li, Y. Liu, J. Zou, Y. Zhu

Erschienen in: Clinical and Translational Oncology | Ausgabe 10/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Mounting studies have investigated the clinicopathological and prognostic value of hypoxia-inducible factor-1α (HIF-1α) in breast cancer (BC), yet conclusions remain controversial. Therefore, we conducted this meta-analysis to clarify this issue.

Methods

All relevant studies were searched using Cochrane Library, Web of Science, PubMed, and EMBASE online databases. Pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs) were applied to evaluate the clinicopathological and prognostic value of HIF-1α, respectively. Subgroup analysis and sensitivity analysis were performed to investigate heterogeneity and stability of the results. Begg’s funnel plot and Egger’s test were used to examine publication bias.

Results

A total of 31 eligible studies including 5177 subjects were enrolled. Of these, 25 studies assessed the prognostic role of HIF-1α and included 4546 individuals. Twenty-three studies involving 3277 individuals evaluated the clinicopathological significance of HIF-1α. High expression level of HIF-1α was correlated with poor overall survival (OS) (HR = 1.59, 95% CI = 1.40–1.80, P < 0.001), disease-free survival (DFS) (HR = 1.87, 95% CI = 1.53–2.28, P < 0.001), relapse-free survival (HR = 1.36, 95% CI = 1.07–1.73, P = 0.001), and cancer-specific survival (HR = 1.55, 95% CI = 1.10–2.19, P = 0.012). Pooled data from studies using multivariate survival analysis also showed that HIF-1α expression was associated with worse OS (HR = 1.59, 95% CI = 1.32–1.92, P < 0.001) and DFS (HR = 1.60, 95% CI = 1.39–1.84, P < 0.001). Additionally, high HIF-1α expression was associated with advanced tumor–node–metastasis stage, positive lymph-node status, negative ER status, ductal type, advanced histologic grade, high Ki67 expression, and strong VEGF expression.

Conclusion

HIF-1α might serve as an independent prognostic biomarker and a promising therapeutic target for BC. Future large-scale prospective randomized trials are needed to confirm our findings.

Nur mit Berechtigung zugänglich

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

Redig AJ, McAllister SS. Breast cancer as a systemic disease: a view of metastasis. J Intern Med. 2013;274:113–26.CrossRefPubMedPubMedCentral

Sopik V, Narod SA. The relationship between tumour size, nodal status and distant metastases: on the origins of breast cancer. Breast Cancer Res Treat. 2018;170(3):647–56. https://doi.org/10.1007/s10549-018-4796-9.CrossRefPubMedPubMedCentral

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, et al. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol Off J Eur Soc Med Oncol. 2011;22(8):1736–47. https://doi.org/10.1093/annonc/mdr304.CrossRef

Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2002;20(17):3628–36. https://doi.org/10.1200/JCO.2002.02.026.CrossRef

Rajkovic-Molek K, Mustac E, Hadzisejdic I, Jonjic N. The prognostic importance of nuclear factor kappaB and hypoxia-inducible factor 1alpha in relation to the breast cancer subtype and the overall survival. Appl Immunohistochem Mol Morphol. 2014;22(6):464–70. https://doi.org/10.1097/PAI.0b013e31829271ce.CrossRefPubMed

Harris AL. Hypoxia—a key regulatory factor in tumour growth. Nat Rev Cancer. 2002;2(1):38–47. https://doi.org/10.1038/nrc704.CrossRefPubMed

Walsh JC, Lebedev A, Aten E, Madsen K, Marciano L, Kolb HC. The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxid Redox Signal. 2014;21(10):1516–54. https://doi.org/10.1089/ars.2013.5378.CrossRefPubMedPubMedCentral

Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995;92(12):5510–4. https://doi.org/10.1073/pnas.92.12.5510.CrossRefPubMedPubMedCentral

10.

Dachs GU, Patterson AV, Firth JD, Ratcliffe PJ, Townsend KM, Stratford IJ, et al. Targeting gene expression to hypoxic tumor cells. Nat Med. 1997;3(5):515–20. https://doi.org/10.1038/nm0597-515.CrossRefPubMed

11.

Masoud GN, Li W. HIF-1alpha pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B. 2015;5(5):378–89. https://doi.org/10.1016/j.apsb.2015.05.007.CrossRefPubMedPubMedCentral

12.

Chen Z, He X, Xia W, Huang Q, Zhang Z, Ye J, et al. Prognostic value and clinicopathological differences of HIFs in colorectal cancer: evidence from meta-analysis. PLoS ONE. 2013;8(12):e80337. https://doi.org/10.1371/journal.pone.0080337.CrossRefPubMedPubMedCentral

13.

Luo D, Ren H, Zhang W, Xian H, Lian K, Liu H. Clinicopathological and prognostic value of hypoxia-inducible factor-1alpha in patients with bone tumor: a systematic review and meta-analysis. J Orthop Surg Res. 2019;14(1):56. https://doi.org/10.1186/s13018-019-1101-5.CrossRefPubMedPubMedCentral

14.

Xie W, Liu L, He H, Yang K. Prognostic value of hypoxia-inducible factor-1 alpha in nasopharyngeal carcinoma: a meta-analysis. Int J Biol Markers. 2018;3:1. https://doi.org/10.1177/1724600818778756.CrossRef

15.

Zheng SS, Chen XH, Yin X, Zhang BH. Prognostic significance of HIF-1alpha expression in hepatocellular carcinoma: a meta-analysis. PLoS ONE. 2013;8(6):e65753. https://doi.org/10.1371/journal.pone.0065753.CrossRefPubMedPubMedCentral

16.

Campbell EJ, Dachs GU, Morrin HR, Davey VC, Robinson BA, Vissers MCM. Activation of the hypoxia pathway in breast cancer tissue and patient survival are inversely associated with tumor ascorbate levels. BMC Cancer. 2019;19(1):307. https://doi.org/10.1186/s12885-019-5503-x.CrossRefPubMedPubMedCentral

17.

Cui J, Jiang H. Prediction of postoperative survival of triple-negative breast cancer based on nomogram model combined with expression of HIF-1alpha and c-myc. Medicine. 2019;98(40):e17370. https://doi.org/10.1097/md.0000000000017370.CrossRefPubMedPubMedCentral

18.

D M, A L, J T, DG A, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg (Lond Engl). 2010;8(5):336–41. https://doi.org/10.1016/j.ijsu.2010.02.007.CrossRef

19.

Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5. https://doi.org/10.1007/s10654-010-9491-z.CrossRefPubMed

20.

Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. https://doi.org/10.1186/1745-6215-8-16.CrossRefPubMedPubMedCentral

21.

Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, et al. Levels of hypoxia-inducible factor-1 alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer. 2003;97(6):1573–81. https://doi.org/10.1002/cncr.11246.CrossRefPubMed

22.

Brito LGO, Schiavon VF, de Andrade JM, Tiezzi DG, Peria FM, Marana HRC. Expression of hypoxia-inducible factor 1-alpha and vascular endothelial growth factor-C in locally advanced breast cancer patients. Clinics. 2011;66(8):1313–9. https://doi.org/10.1590/s1807-59322011000800002.CrossRefPubMedPubMedCentral

23.

Cai FF, Xu C, Pan X, Cai L, Lin XY, Chen S, et al. Prognostic value of plasma levels of HIF-1a and PGC-1a in breast cancer. Oncotarget. 2016;7(47):77793–806. https://doi.org/10.18632/oncotarget.12796.CrossRefPubMedPubMedCentral

24.

Chen HHW, Su WC, Lin PW, Guo HR, Lee WY. Hypoxia-inducible factor-1 alpha correlates with MET and metastasis in node-negative breast cancer. Breast Cancer Res Treat. 2007;103(2):167–75. https://doi.org/10.1007/s10549-006-9360-3.CrossRefPubMed

25.

Dales JP, Garcia S, Meunier-Carpentier S, Andrac-Meyer L, Haddad O, Lavaut MN, et al. Overexpression of hypoxia-inducible factor HIF-1 alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int J Cancer. 2005;116(5):734–9. https://doi.org/10.1002/ijc.20984.CrossRefPubMed

26.

Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Wigfield S, et al. Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2006;12(15):4562–8. https://doi.org/10.1158/1078-0432.ccr-05-2690.CrossRef

27.

Giatromanolaki A, Koukourakis MI, Simopoulos C, Polychronidis A, Gatter KC, Harris AL, et al. c-erbB-2 related aggressiveness in breast cancer is hypoxia inducible factor-1alpha dependent. Clin Cancer Res Off J Am Assoc Cancer Res. 2004;10(23):7972–7. https://doi.org/10.1158/1078-0432.ccr-04-1068.CrossRef

28.

Gruber G, Greiner RH, Hlushchuk R, Aebersold DM, Altermatt HJ, Berclaz G, et al. Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter? Breast Cancer Res. 2004;6(3):R191–R198198. https://doi.org/10.1186/bcr775.CrossRefPubMedPubMedCentral

29.

Hyseni A, van der Groep P, van der Wall E, van Diest PJ. Subcellular FIH-1 expression patterns in invasive breast cancer in relation to HIF-1 alpha expression. Cell Oncol. 2011;34(6):565–70. https://doi.org/10.1007/s13402-011-0053-5.CrossRef

30.

Jeon HM, Kim DH, Jung WH, Koo JS. Expression of cell metabolism-related genes in different molecular subtypes of triple-negative breast cancer. Tumori. 2013;99(4):555–64.CrossRefPubMed

31.

Jin MS, Lee H, Park IA, Chung YR, Im SA, Lee KH, et al. Overexpression of HIF1 alpha and CAXI predicts poor outcome in early-stage triple negative breast cancer. Virchows Arch. 2016;469(2):183–90. https://doi.org/10.1007/s00428-016-1953-6.CrossRefPubMed

32.

Kaya AO, Gunel N, Benekli M, Akyurek N, Buyukberber S, Tatli H, et al. Hypoxia inducible factor-1 alpha and carbonic anhydrase IX overexpression are associated with poor survival in breast cancer patients. J BUON. 2012;17(4):663–8.PubMed

33.

Kim HO, Jo YH, Lee J, Lee SS, Yoon KS. The C1772T genetic polymorphism in human HIF-1alpha gene associates with expression of HIF-1alpha protein in breast cancer. Oncol Rep. 2008;20(5):1181–7.PubMed

34.

Kronblad A, Jirstrom K, Ryden L, Nordenskjold B, Landberg G. Hypoxia inducible factor-1 alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response. Int J Cancer. 2006;118(10):2609–16. https://doi.org/10.1002/ijc.21676.CrossRefPubMed

35.

Li M, Xiao D, Zhang J, Qu H, Yang Y, Yan Y, et al. Expression of LPA2 is associated with poor prognosis in human breast cancer and regulates HIF-1 expression and breast cancer cell growth. Oncol Rep. 2016;36(6):3479–87. https://doi.org/10.3892/or.2016.5206.CrossRefPubMed

36.

Malfettone A, Saponaro C, Paradiso A, Simone G, Mangia A. Peritumoral vascular invasion and NHERF1 expression define an immunophenotype of grade 2 invasive breast cancer associated with poor prognosis. BMC Cancer. 2012;12:106. https://doi.org/10.1186/1471-2407-12-106.CrossRefPubMedPubMedCentral

37.

Nalwoga H, Ahmed L, Arnes JB, Wabinga H, Akslen LA. Strong expression of hypoxia-inducible factor-1alpha (HIF-1alpha) is associated with Axl expression and features of aggressive tumors in African breast cancer. PLoS ONE. 2016;11(1):e0146823. https://doi.org/10.1371/journal.pone.0146823.CrossRefPubMedPubMedCentral

38.

Ni X, Zhao Y, Ma J, Xia T, Liu X, Ding Q, et al. Hypoxia-induced factor-1 alpha upregulates vascular endothelial growth factor C to promote lymphangiogenesis and angiogenesis in breast cancer patients. J Biomed Res. 2013;27(6):478–85. https://doi.org/10.7555/jbr.27.20130021.CrossRefPubMedPubMedCentral

39.

Nie C, Lv H, Bie L, Hou H, Chen X. Hypoxia-inducible factor 1-alpha expression correlates with response to neoadjuvant chemotherapy in women with breast cancer. Medicine. 2018;97(51):e13551. https://doi.org/10.1097/md.0000000000013551.CrossRefPubMedPubMedCentral

40.

Okada K, Osaki M, Araki K, Ishiguro K, Ito H, Ohgi S. Expression of hypoxia-inducible factor (HIF-1alpha), VEGF-C and VEGF-D in non-invasive and invasive breast ductal carcinomas. Anticancer Res. 2005;25(4):3003–9.PubMed

41.

Peng JH, Wang XL, Ran L, Song JL, Luo R, Wang YH. Hypoxia-inducible factor 1 alpha regulates the transforming growth factor beta 1/SMAD family member 3 pathway to promote breast cancer progression. J Breast Cancer. 2018;21(3):259–66. https://doi.org/10.4048/jbc.2018.21.e42.CrossRefPubMedPubMedCentral

42.

Peurala E, Koivunen P, Bloigu R, Haapasaari KM, Jukkola-Vuorinen A. Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients. Breast Cancer Res Treat. 2012;133(1):179–88. https://doi.org/10.1007/s10549-011-1750-5.CrossRefPubMed

43.

Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, et al. Overexpression of hypoxia-inducible factor 1 alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin Cancer Res. 2002;8(6):1831–7.PubMed

44.

Shi L, Zhao CB, Pu HH, Zhang QY. FBP1 expression is associated with basal-like breast carcinoma. Oncol Lett. 2017;13(5):3046–56. https://doi.org/10.3892/ol.2017.5860.CrossRefPubMedPubMedCentral

45.

Tan EY, Campo L, Han C, Turley H, Pezzella F, Gatter KC, et al. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13(2 Pt 1):467–74. https://doi.org/10.1158/1078-0432.ccr-06-1466.CrossRef

46.

Trastour C, Benizri E, Ettore F, Ramaioli A, Chamorey E, Pouyssegur J, et al. HIF-1alpha and CA IX staining in invasive breast carcinomas: prognosis and treatment outcome. Int J Cancer. 2007;120(7):1451–8. https://doi.org/10.1002/ijc.22436.CrossRefPubMed

47.

Vleugel MM, Greijer AE, Shvarts A, van der Groep P, van Berkel M, Aarbodem Y, et al. Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol. 2005;58(2):172–7. https://doi.org/10.1136/jcp.2004.019885.CrossRefPubMedPubMedCentral

48.

Yamamoto Y, Ibusuki M, Okumura Y, Kawasoe T, Kai K, Iyama K, et al. Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. Breast Cancer Res Treat. 2008;110(3):465–75. https://doi.org/10.1007/s10549-007-9742-1.CrossRefPubMed

49.

Nepal M, Choi HJ, Choi BY, Kim SL, Ryu JH, Kim DH, et al. Anti-angiogenic and anti-tumor activity of Bavachinin by targeting hypoxia-inducible factor-1alpha. Eur J Pharmacol. 2012;691(1–3):28–37. https://doi.org/10.1016/j.ejphar.2012.06.028.CrossRefPubMed

50.

Marignol L, Rivera-Figueroa K, Lynch T, Hollywood D. Hypoxia, notch signalling, and prostate cancer. Nat Rev Urol. 2013;10(7):405–13. https://doi.org/10.1038/nrurol.2013.110.CrossRefPubMedPubMedCentral

51.

Wang W, He YF, Sun QK, Wang Y, Han XH, Peng DF, et al. Hypoxia-inducible factor 1alpha in breast cancer prognosis. Clin Chim Acta Int J Clin Chem. 2014;428:32–7. https://doi.org/10.1016/j.cca.2013.10.018.CrossRef

52.

Marton I, Knezevic F, Ramic S, Milosevic M, Tomas D. Immunohistochemical expression and prognostic significance of HIF-1alpha and VEGF-C in neuroendocrine breast cancer. Anticancer Res. 2012;32(12):5227–322.PubMed

53.

Yan M, Rayoo M, Takano EA, Investigators KC, Fox SB. BRCA1 tumours correlate with a HIF-1alpha phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression. Br J Cancer. 2009;101(7):1168–74. https://doi.org/10.1038/sj.bjc.6605287.CrossRefPubMedPubMedCentral

54.

Kalemkerian GP, Narula N, Kennedy EB, Biermann WA, Donington J, Leighl NB, et al. Molecular testing guideline for the selection of patients with lung cancer for treatment with targeted tyrosine kinase inhibitors: american society of clinical oncology endorsement of the college of american pathologists/international association for the study of lung cancer/association for molecular pathology clinical practice guideline update. J Clin Oncol: Official J Amer Soc Clin Oncol. 2018;36(9):911–9. https://doi.org/10.1200/JCO.2017.76.7293.CrossRef

55.

Han S, Huang T, Hou F, Yao L, Wang X, Wu X. The prognostic value of hypoxia-inducible factor-1alpha in advanced cancer survivors: a meta-analysis with trial sequential analysis. Ther Adv Med Oncol. 2019;11:1758835919875851. https://doi.org/10.1177/1758835919875851.CrossRefPubMedPubMedCentral

Titel: Clinicopathological and prognostic value of hypoxia-inducible factor-1α in breast cancer: a meta-analysis including 5177 patients
verfasst von: Z. Zhao
H. Mu
Y. Li
Y. Liu
J. Zou
Y. Zhu
Publikationsdatum: 12.03.2020
Verlag: Springer International Publishing
Erschienen in: Clinical and Translational Oncology / Ausgabe 10/2020
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-020-02332-8

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Clinicopathological and prognostic value of hypoxia-inducible factor-1α in breast cancer: a meta-analysis including 5177 patients

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2020

THBS1 facilitates colorectal liver metastasis through enhancing epithelial–mesenchymal transition

Expression-based, consistent biomarkers for prognosis and diagnosis in lung cancer

Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population

Current updates on the role of reactive oxygen species in bladder cancer pathogenesis and therapeutics

Brain metastases treated with radiosurgery or hypofractionated stereotactic radiotherapy: outcomes and predictors of survival

VMAT partial-breast irradiation: acute toxicity of hypofractionated schedules of 30 Gy in five daily fractions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie